Business

Know the Business

Hims & Hers is a direct-to-consumer subscription pharmacy wrapped in a thin telehealth layer — customers come for generic, lifestyle-sensitive prescriptions (hair, sex, weight, skin, mood), and the real business is the $800M-a-year marketing machine that converts them into recurring refill-shippers at a 6–7 month payback. The bull case is that personalized, vertically-integrated fulfillment is the moat and GLP-1 is just kindling; the bear case is that this is a paid-acquisition retailer masquerading as healthcare, whose best-margin line (compounded semaglutide) is living on regulatory time. The market is almost certainly overweighting GLP-1 headlines and underweighting the fact that the majority of FY25 revenue already comes from non-GLP-1 offerings compounding at high double-digit rates.

How This Business Actually Works

The engine is a three-step loop: buy a customer with advertising, route them through an algorithmic clinical workflow, and ship them compounded or generic product on a recurring cadence. Every improvement to that loop — a cheaper ad channel, a higher-priced personalized SKU, a longer retention tail — shows up quickly in unit economics.

Three features determine whether this loop actually makes money:

1. Payback under one year, not cohort LTV. Management runs marketing to a 6–7 month gross-profit payback — the weakest discipline on the P&L is actually the most disciplined. Marketing dropped from 51% of revenue in FY23 to 39% in FY25 despite a Super Bowl ad; that is the leverage, not the 74% gross margin.
2. Personalization is pricing power, not clinical breakthrough. "Personalized" = a multi-drug or multi-dose compound that is (a) not a generic equivalent, (b) not reimbursable, and (c) only available on the platform. In FY25 personalized crossed 70% of US revenue, which is why ARPU jumped 28% to $83 despite only 13% subscriber growth.
3. Vertical fulfillment converts scale into margin, slowly. Four pharmacies, a 503B outsourcing facility, a peptide facility, and a lab facility — 1M sq ft and $300M of capex over three years. The quid pro quo is the FY25 gross-margin dip to 74% (from 82% in FY23) as weight-loss shipping cadence and international mix weigh on the mix. Management is betting that owned manufacturing eventually pulls it back.

The story on this chart is the orange line. Gross margin has been drifting down for two years. What flipped the economics was marketing efficiency as the brand scaled and the subscriber base got old enough to contribute free revenue.

The Playing Field

Hims & Hers has no real peer at scale. The "DTC telehealth" category is an optical illusion — put it next to the only company with comparable revenue (Teladoc), and it's a completely different business, and put it next to the businesses with the same model (LifeMD), and it's ten to twelve times their size.

Three observations the peer set forces on you:

• No one else is growing and making money. Teladoc is a declining B2B/payer business; American Well is still burning 40 cents for every revenue dollar after a decade; WW is the post-bankruptcy shell of a category that GLP-1s broke. HIMS is the only company in this set that is positive on both axes.
• The closest analog is LifeMD, at 1/12th the size. LFMD is the honest comp — DTC Rx subscription, similar ARPU, better gross margin, slower growth, sub-scale marketing. It shows what HIMS would look like without the brand and the Super Bowl budget.
• "Telehealth market share" is the wrong frame. Management cites being "roughly twice the size of the next largest U.S. telehealth provider" on a transaction-panel basis (Bloomberg Second Measure, sexual health / derm / mental health / weight loss). That is a DTC subscription-pharmacy slice, not the broader telehealth market Teladoc competes in. Treat the TAM claims accordingly.

The more interesting competitor is not in this table: it's Amazon Pharmacy + One Medical and the branded GLP-1 manufacturers (Novo, Lilly) direct-to-consumer. Amazon's November 2024 push into telehealth knocked the stock; its April 2026 weight-loss program did the same. This is where the threat lives, not in the publicly traded "telehealth" peer group.

Is This Business Cyclical?

Not in the classical macro sense — subscription health/wellness is shallowly discretionary and GDP-insensitive. The real cycle is regulatory, and it runs on an unpredictable clock.

The stock has oscillated 20–50% in single weeks on these events. A few things to understand about the mechanism:

Where the cycle actually hits: not demand (subscribers still want cheaper Ozempic); not pricing (compounded is already the cheap version); but legal right to exist. A single FDA list update can take a $200M/year product category off the platform in a quarter. Weight-loss offerings carry shorter shipping cadences and heavier fulfillment costs, which is why FY25 gross margin fell 500 bps — so the category is also the lowest-margin one to defend.

The comforting counter-fact: management has been explicit that the majority of FY25 revenue came from non-GLP-1 offerings, and Hers (weight-loss + derm) still grew >100% despite the February 2026 FDA statement naming the company. Each of Hims and Hers has multiple $100M+ specialties — sexual health, hair loss, and dermatology predate GLP-1s and keep compounding. Pull GLP-1 out of the model and you still have a profitable, growing DTC subscription pharmacy; you just don't have a 60% top-line growth rate.

Macro exposure is real but second-order. Consumer discretionary cuts would hit CAC efficiency (ad auction inflation) and retention at the margin. Trade and tariff actions on API sourcing would hit COGS. Neither of these is in the stock today.

The Metrics That Actually Matter

Forget the traditional retail-pharma ratios. There are really five numbers that decide whether this company is creating value.

What I'd Tell a Young Analyst

Stop thinking of this as a telehealth company. It is a DTC subscription pharmacy with a Super Bowl ad budget. Model it like Dollar Shave Club with compounded prescriptions, not like Teladoc. Every analytical mistake on this name comes from using the wrong comp set.

Separate GLP-1 from the rest of the business in your model. Build two lines: a base case (everything but compounded semaglutide/tirzepatide) and an optional GLP-1 contribution. The base case is profitable, 30–40% growth, 70%+ personalized mix, durable. The GLP-1 line is a binary regulatory bet worth modeling as an option. Most sell-side decks blend these and get surprised both directions.

Three things would change the thesis. First, marketing payback extending past 12 months (historically stable at 6–7 — if that breaks, the whole model is cosmetic). Second, FCF failing to recover in 2026 as capex rolls off — management has been investing $300M in facilities, and if that doesn't earn its return by 2027 the owned-pharmacy story is bluster. Third, a definitive FDA move on GLP-1 compounding that doesn't just restrict it but also drags non-GLP-1 compounding into its ambit (testosterone, minoxidil personalization) — this is the tail risk nobody is modeling.

What the market is underestimating: Eucalyptus (up to $1.15B, closes mid-2026) makes HIMS a genuine global DTC health platform with $450M+ of international run-rate revenue and access to Australia, Germany, UK, Japan, Canada in one stroke. That changes the TAM conversation and gives management a runway to hit the 2030 target of $6.5B revenue / $1.3B EBITDA even if US GLP-1 evaporates. Almost nobody in the US telehealth conversation is pricing Eucalyptus.

What the market is overestimating: the durability of the 2025 gross-margin story. Gross margin fell 500 bps in a year and will keep drifting as weight-loss, international, and new specialties mix in. Management will tell you scale fixes it; history says mix wins. If you build your model with stable 74% gross margin, you are almost certainly wrong.

Watch Q1 FY26 for two tells: the pace at which compounded GLP-1 revenue shrinks post-FDA statement, and whether the payback period stays inside 8 months. Those two numbers dictate whether 2026 guidance of $2.7–2.9B revenue / $300–375M Adj EBITDA is conservative or brave.